LUNG

2.5706.20%
DS

Derrick Sung

CFO & COO

Dr. Derrick Sung, Ph.D. is Chief Operating Officer and Chief Financial Officer at Pulmonx Corporation since November 03, 2025. He served as the Chief Financial Officer at Aerin Medical Inc from November 2023 to December 2025. He has finance, capital markets and strategy experience across diverse roles within the medical device industry. He spent seven years on Wall Street as senior equity research Analyst covering the medical devices sector, directed marketing and business development for Boston Scientific's Neuromodulation division, led management consulting engagements at the Boston Consulting Group and designed heart catheters as an R&D engineer for Guidant Corporation. Dr. Sung has served on the board of directors of Sensydia Corporation since August 2018. He was Independent Director of Minerva Surgical, Inc. from July 2022 until 2024. Dr. Sung served as the Executive Vice President of Strategy and Corporate Development for iRhythm Technologies Inc. He served as Chief Financial Officer at Pulmonx Corporation from May 9, 2019 to October 10, 2023. Dr. Sung remained as an Employee of Pulmonx Corporation in an advisory role to the executive leadership team through October 31, 2023. He served as an Executive Vice President of Strategy and Corporate Development at iRhythm Technologies, Inc. since May 2015 until May 2019. Dr. Sung was responsible for driving new revenue opportunities by monetizing iRhythm's rapidly growing proprietary algorithms and patient database in mobile applications, analytics for consumer health monitoring and biomarker discovery. From February 2008 to April 2015, Dr. Sung served as a Senior Research Analyst at Sanford C. Bernstein & Co. LLC, Research Division. He joined the firm in 2008 and covered the United States medical devices sector. From 2004 to 2008, Dr. Sung served as the Director of Marketing and Business Development for the neuromodulation division at Boston Scientific Corporation. From 2000 to 2004, Dr. Sung was a Management Consultant at the Boston Consulting Group, where he advised med tech and biopharma companies on a variety of strategic and operational issues. Dr. Sung began his career as Research and Development Engineer at Guidant Corporation. He is a trained Engineer and designed Heart Catheters at the Guidant division part of Abbott Labs. Dr. Sung holds a Ph. D. in Bioengineering from the University of California, San Diego, an M.B.A. from San Diego State University and a B.S. in Mechanical Engineering from Stanford University.

Positions